TY - JOUR
T1 - Intrahepatic plasma cells, but not atypical memory B cells, associate with clinical phases of chronic hepatitis B
AU - Osmani, Zgjim
AU - Villanueva, Martin Arreola
AU - Joseph-Chazan, Jasmin
AU - Beudeker, Boris J
AU - de Knegt, Robert J
AU - Chung, Raymond T
AU - Hacohen, Nir
AU - Aerssens, Jeroen
AU - Bollekens, Jacques
AU - Janssen, Harry L A
AU - Gehring, Adam J
AU - Lauer, Georg M
AU - Shalek, Alex K
AU - van de Werken, Harmen J G
AU - Boonstra, Andre
N1 - Publisher Copyright:
© 2024 The Author(s). European Journal of Immunology published by Wiley-VCH GmbH.
PY - 2024/9
Y1 - 2024/9
N2 - Studies have traditionally focused on the role of T cells in chronic hepatitis B (CHB), but recent evidence supports a role for B cells. The enrichment of so-called atypical memory (AtM) B cells, which show reduced signaling and impaired differentiation, is believed to be a characteristic feature of CHB, potentially contributing to the observed dysfunctional anti-HBsAg B-cell responses. Our study, involving 62 CHB patients across clinical phases, identified AtM B cells expressing IFNLR1 and interferon-stimulated genes. Contrary to previous reports, we found relatively low frequencies of AtM B cells in the liver, comparable to peripheral blood. However, liver plasma cell frequencies were significantly higher, particularly during phases with elevated viral loads and liver enzyme levels. Liver plasma cells exhibited signs of active proliferation, especially in the immune active phase. Our findings suggest a potential role for plasma cells, alongside potential implications and consequences of local proliferation, within the livers of CHB patients. While the significance of AtM B cells remains uncertain, further investigation is warranted to determine their responsiveness to interferons and their role in CHB.
AB - Studies have traditionally focused on the role of T cells in chronic hepatitis B (CHB), but recent evidence supports a role for B cells. The enrichment of so-called atypical memory (AtM) B cells, which show reduced signaling and impaired differentiation, is believed to be a characteristic feature of CHB, potentially contributing to the observed dysfunctional anti-HBsAg B-cell responses. Our study, involving 62 CHB patients across clinical phases, identified AtM B cells expressing IFNLR1 and interferon-stimulated genes. Contrary to previous reports, we found relatively low frequencies of AtM B cells in the liver, comparable to peripheral blood. However, liver plasma cell frequencies were significantly higher, particularly during phases with elevated viral loads and liver enzyme levels. Liver plasma cells exhibited signs of active proliferation, especially in the immune active phase. Our findings suggest a potential role for plasma cells, alongside potential implications and consequences of local proliferation, within the livers of CHB patients. While the significance of AtM B cells remains uncertain, further investigation is warranted to determine their responsiveness to interferons and their role in CHB.
UR - http://www.scopus.com/inward/record.url?scp=85195107540&partnerID=8YFLogxK
U2 - 10.1002/eji.202451085
DO - 10.1002/eji.202451085
M3 - Article
C2 - 38813721
SN - 0014-2980
VL - 54
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 9
M1 - 2451085
ER -